The DOI matches its Crossref record; 68 of the 76 references it cites were found in a registry or an index; none of the 25 sources its claims cite is checked for support yet.
Transporter-Mediated Drug Interaction Strategy for 5-Aminolevulinic Acid (ALA)-Based Photodynamic Diagnosis of Malignant Brain Tumor: Molecular Design of ABCG2 Inhibitors
Open accessAbstract
Photodynamic diagnosis (PDD) is a practical tool currently used in surgical operation of aggressive brain tumors, such as glioblastoma. PDD is achieved by a photon-induced physicochemical reaction which is induced by excitation of protoporphyrin IX (PpIX) exposed to light. Fluorescence-guided gross-total resection has recently been developed in PDD, where 5-aminolevulinic acid (ALA) or its ester is administered as the precursor of PpIX. ALA induces the accumulation of PpIX, a natural photo-sensitizer, in cancer cells. Recent studies provide evidence that adenosine triphosphate (ATP)-binding cassette (ABC) transporter ABCG2 plays a pivotal role in regulating the cellular accumulation of porphyrins in cancer cells and thereby affects the efficacy of PDD. Protein kinase inhibitors are suggested to potentially enhance the PDD efficacy by blocking ABCG2-mediated porphyrin efflux from cancer cells. It is of great interest to develop potent ABCG2-inhibitors that can be applied to PDD for brain tumor therapy. This review article addresses a pivotal role of human ABC transporter ABCG2 in PDD as well as a new approach of quantitative structure-activity relationship (QSAR) analysis to design potent ABCG2-inhibitors.
Overview
CoChat Summary
TL;DR
This review argues that ABCG2 is a key regulator of 5-ALA–induced protoporphyrin IX (PpIX) accumulation in brain tumors and that short-term ABCG2 inhibition could improve intra-operative photodynamic diagnosis (PDD). It also summarizes structure–activity and molecular-orbital analyses suggesting that several protein kinase inhibitors, especially gefitinib and some CDK inhibitors, can inhibit ABCG2.
Key findings
- In fluorescence-guided neurosurgery, approximately 80% to 90% of malignant gliomas show red fluorescence after ALA administration, and clinical data indicate that ALA-photodynamic diagnosis-assisted resection of malignant gliomas results in statistically significant prolongation of postoperative survival.
- In a study of 20 tumor samples from brain tumor patients, qRT-PCR showed that CPOX mRNA was markedly increased in malignant brain tumors with strong PpIX fluorescence; the high CPOX mRNA level was significantly correlated with strong 5-ALA-induced fluorescence and PpIX accumulation.
- The paper reports that ABCG2 mRNA was lower in malignant glioma cells from brain tumors with strong PpIX fluorescence, and interprets this as facilitating intracellular PpIX accumulation because ABCG2 exports porphyrins.
- Gefitinib inhibited ABCG2-mediated transport very effectively, with an IC50 of 0.28 μM using methotrexate as the model substrate; QSAR analysis gave R² = 0.920 and F = 50.1, and predicted 10 μM gefitinib would inhibit ABCG2-mediated MTX transport by 104%.
Methods
- Review article synthesizing prior work on PDD, porphyrin biology, ABCG2 transport, and inhibitor design; no new clinical trial or animal experiment is presented as the paper’s main design.
- The paper summarizes a molecular biology study in which qRT-PCR measured mRNA levels of porphyrin-pathway genes in 20 surgically resected brain tumor samples, with immunohistochemistry used to confirm CPOX findings.
- It also summarizes QSAR analysis of ABCG2 inhibition using chemical fragmentation codes, plus ab initio molecular orbital calculations to compare 3D structures of protein kinase inhibitors and relate structure to ABCG2 inhibition.
Limitations
- The paper explicitly states that further clinical research is needed to prove the concept of using a short-term, limited-dose ABCG2 inhibitor during intra-operative PDD.
- It also notes that the accurate mechanisms of ABCG2-mediated transport remain uncertain because no crystal structures are available for human ABCG2 and homology models have not been experimentally validated.
- Evident from the text: this is a review, so the proposed clinical strategy is not directly tested here.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2. Preoperative Gd-enhanced MRI scanning and 5-ALA-induced tumor fluorescence. (A) Glioblastoma with strong red fluorescence; (B) metastatic brain tumor with no red fluorescence. Circular lines show the tumor location in operative view. Data are from reference [33].](https://figures.cochat.ai/paper-figures/68bc5070ddf5424e88eb2c165bda9312/transporter-mediated-drug-interaction-strategy-for-5-aminolevulinic-acid-ala-figure-2.jpg)
![Figure 3. Enhanced expression of CPOX gene in glioblastoma with strong red fluorescence. (A) Comparison of the mRNA levels of PEPT1, PEPT2, ALAD, HMBS, UROS, UROD, ABCB6, CPOX, PPOX, ABCG2, FECH, HO-1, ALAS1, ALAS2, and HIF-1 genes between the “no fluorescence” and “strong fluorescence” groups. Gene names: PEPT1, oligopeptide transporter 1; PEPT2, oligopeptide transporter 2; ALAD, delta-aminolevulinate dehydratase; HMBS, hydroxymethylbilane synthase; UROS, uroporphyrinogen III synthase; UROD, uroporphyrinogen decarboxylase; ABCB6, ABC transporter B6; CPOX, coproporphyrinogen oxidase; PPOX, protoporphyrinogen oxidase; ABCG2, ABC transporter G2 (BCRP); FECH, ferrochelatase; HO-1, heme oxygenase 1; ALAS1, 5-aminolevulinate synthase 1; ALAS2, 5-aminolevulinate synthase 2; HIF-1, hypoxia inducible factor-1 alpha subunit. Total RNA was extracted from brain tumor areas, and the first strand cDNA was prepared from the extracted total RNA in a reverse transcriptase (RT) reaction. Quantitative PCR was performed as described previously [33]. The mRNA levels of these genes are normalized to the mRNA level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Data are expressed as means ± SD (N = 10) [33]; (B) Statistical analysis of CPOX mRNA levels between the “no fluorescence” and the “strong fluorescence” groups. Data are expressed as means ± SD (N = 10) [33]. (C) HPLC elution profile of porphyrins in brain tumor samples with strong red fluorescence. HPLC analysis was performed as described previously [34]. As the standards, uroporphyrin 1 (UPI), Uroporphyrin III (UPIII), Coproprophyrin I (CPI), Coproprophyrin III (CPIII), and protoporphyrin IX (PpIX) were eluted at retention times of 7.3, 8.0, 20.0, 205, and 34.5 min, respectively.](https://figures.cochat.ai/paper-figures/d86e8f4b17d049558385897f1aac5d01/transporter-mediated-drug-interaction-strategy-for-5-aminolevulinic-acid-ala-figure-3.jpg)



![Figure 7. (A) Inhibition of ABCG2-mediated MTX transport by gefitinib. Experimental procedures and conditions are described previously [47]. The chemical structure of gefitinib is depicted in this figure. (B) Relationship between observed and predicted values in the inhibition of ABCG2-mediated MTX transport by different test compounds. The inhibition by gefitinib is indicated by an open circle (○). Data are from [47].](https://figures.cochat.ai/paper-figures/504dff4f6b93424aa867eb7268438e20/transporter-mediated-drug-interaction-strategy-for-5-aminolevulinic-acid-ala-figure-7.jpg)
![Figure 8. Chemical structures of CDK inhibitors: purvalanol A, WHI-P180, roscovitine, bohemine, and olomoucine. Chemical fragmentation codes involved in these CDK inhibitors were deduced by using the Markush TOPFRAG program (http://thomsonderwent.com/products/patentresarch/markushtopfrag/) (Derwent Information Ltd., London, UK) as described previously [47]. Information of each chemical fragmentation code is briefly summarized in Table 1.](https://figures.cochat.ai/paper-figures/95a2ef63b9dc4a9fbb50dd2f6c94f858/transporter-mediated-drug-interaction-strategy-for-5-aminolevulinic-acid-ala-figure-8.jpg)
![Figure 9. Putative three-dimensional (3D) structures of purvalanol A, WHI-P180, gefitinib, roscovitine, bohemine, roscovitine, and olomoucine. The 3D structures (A) and the highest occupied molecular orbits (HOMO) (B) of those CDK inhibitors were generated by ab initio MO calculation as described previously [50].](https://figures.cochat.ai/paper-figures/5b722f8f017645159f473ee1191f78d3/transporter-mediated-drug-interaction-strategy-for-5-aminolevulinic-acid-ala-figure-9.jpg)
![Figure 10. Inhibition of ABCG2-mediated hematoporphyrin transport by purvalanol A, WHI-P180, roscovitine, bohemine, or olomoucine. ABCG2-expressing plasma membrane vesicles (20 μg of protein) were incubated with 20 μM hematoporphyrin in the presence of purvalanol A, WHI-P180, roscovitine, bohemine, or olomoucine (final concentration: 0, 0.3, 1, 3, 10, or 30 μM) in the standard incubation medium (0.25 M sucrose and 10 mM Tris/HEPES, pH 7.4, 1 mM ATP, 10 mM creatine phosphate, 100 μg/mL of creatine kinase, 10 mM MgCl2) at 37 °C for 10 min. Hematoporphyrin transported into membrane vesicles was detected [50]. Data are expressed as mean values ± SD (n = 5).](https://figures.cochat.ai/paper-figures/cf4d84ff6ed04568a4ef473a13ebfeb8/transporter-mediated-drug-interaction-strategy-for-5-aminolevulinic-acid-ala-figure-10.jpg)
Verification
Claims the paper makes
0 Valid · 0 Not valid · 14 Not checked · 20 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The high mRNA level of CPOX expression was significantly well correlated with the phenotype of strong 5-ALA induced fluorescence (Figure 3B)”
§ Transporter-Mediated Drug Interaction Strategy for 5-Aminolevulinic Acid (ALA)-Based Photodynamic Diagnosis of Malignant Brain Tumor: Molecular Design of ABCG2 Inhibitors > Photodynamic Diagnosis and Fluorescence-Guided Microsurgery
boostedstates an associationn = 20- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Approximately 80% to 90% of the malignant gliomas show this red fluorescence in surgery (Figure 2A), while only a limited number of metastatic brain tumor cases do not (Figure 2B).”
§ Transporter-Mediated Drug Interaction Strategy for 5-Aminolevulinic Acid (ALA)-Based Photodynamic Diagnosis of Malignant Brain Tumor: Molecular Design of ABCG2 Inhibitors > Photodynamic Diagnosis and Fluorescence-Guided Microsurgery
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Interestingly, gefitinib inhibits ABCG2-mediated transport very effectively.”
- Also stated in: § Inhibition of ABCG2 by Gefitinib, Imatinib, and Cyclin-Dependent Kinase (CDK) Inhibitors · hedged
“The IC50 value was estimated to be 0.28 μM, when methotrexate (MTX) was used as a model substrate (Figure 7A).”
§ Transporter-Mediated Drug Interaction Strategy for 5-Aminolevulinic Acid (ALA)-Based Photodynamic Diagnosis of Malignant Brain Tumor: Molecular Design of ABCG2 Inhibitors > Inhibition of ABCG2 by Gefitinib, Imatinib, and Cyclin-Dependent Kinase (CDK) Inhibitors
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Inhibition of ABCG2 by Gefitinib, Imatinib, and Cyclin-Dependent Kinase (CDK) Inhibitors · hedged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We found that the level of mRNA encoding coproporphyrinogen oxidase (CPOX) was remarkably increased in malignant brain tumors that exhibited strong fluorescence of PpIX after 5-ALA administration (Figure 3A).”
§ Transporter-Mediated Drug Interaction Strategy for 5-Aminolevulinic Acid (ALA)-Based Photodynamic Diagnosis of Malignant Brain Tumor: Molecular Design of ABCG2 Inhibitors > Photodynamic Diagnosis and Fluorescence-Guided Microsurgery
plainstates an associationn = 20- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The high mRNA level of CPOX expression was significantly well correlated with the phenotype of strong 5-ALA induced fluorescence (Figure 3B) and accumulation of PpIX in malignant brain tumors (Figure 3C).”
§ Transporter-Mediated Drug Interaction Strategy for 5-Aminolevulinic Acid (ALA)-Based Photodynamic Diagnosis of Malignant Brain Tumor: Molecular Design of ABCG2 Inhibitors > Photodynamic Diagnosis and Fluorescence-Guided Microsurgery
boostedstates an associationn = 20- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
23 more claims
Create a free account to see all 34 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 5
- Probably not a substantial claim. 1
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“Takahashi, K., Ikeda, N., Nonoguchi, N., Kajimoto, Y., Miyatake, S., Hagiya, Y., Ogura, S., Nakagawa, H., Ishikawa, T., and Kuroiwa, T. (2011). Enhanced expression of coproporphyrinogen oxidase in malignant brain tumors: CPOX expression and 5-ALA-induced fluorescence. Neuro-Oncology, In Press.”
Cited work 10.1093/neuonc/nor116 · retracted 2013-07-01 · notice 10.1093/neuonc/not060 · this paper published 2011-09-14
Citations
Cites
1 retracted
Takahashi, K., Ikeda, N., Nonoguchi, N., Kajimoto, Y., Miyatake, S.-I., Hagiya, Y., Ogura, S.-I., Nakagawa, H., Ishikawa, T., & Kuroiwa, T. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor116 · Cited by 46 · cited 5×
“Data are expressed as means ± SD (N = 10) [33]; (B) Statistical analysis of CPOX mRNA levels between the “no fluorescence” and the “strong fluorescence” groups.”
BackgroundMethodInfluentialSelf-citationRetractedPhotodynamic therapy for cancer
Dolmans, D. E. J. G. J., Fukumura, D., & Jain, R. K. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1071 · Cited by 6,758
Stummer, W., Pichlmeier, U., Meinel, T., Wiestler, O. D., Zanella, F., & Reulen, H.-J. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70665-9 · Cited by 3,423
Lacroix, M., Abi-Said, D., Fourney, D. R., Gokaslan, Z. L., Shi, W., DeMonte, F., Lang, F. F., McCutcheon, I. E., Hassenbusch, S. J., Holland, E., et al. (2001) · Journal of Neurosurgery · doi:10.3171/jns.2001.95.2.0190 · Cited by 3,091
A multidrug resistance transporter from human MCF-7 breast cancer cells
Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., & Ross, D. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15665 · Cited by 2,322
Photoradiation therapy for the treatment of malignant tumors.
Dougherty, T. J., Kaufman, J., Goldfarb, A., Weishaupt, K. R., Boyle, D. G., & Mittleman, A. (1978) · PubMed · Cited by 1,834
Identification of singlet oxygen as the cytotoxic agent in photoinactivation of a murine tumor.
Weishaupt, K. R., Gomer, C. J., & Dougherty, T. J. (1976) · PubMed · Cited by 1,647
Protein Kinase Inhibitors: Insights into Drug Design from Structure
Noble, M. E. M., Endicott, J. A., & Johnson, L. N. (2004) · Science · doi:10.1126/science.1095920 · Cited by 1,198
Kennedy (1992) · doi:10.1016/1011-1344(92)85108-7 · Cited by 1,166
Miyake, K., Mickley, L. A., Litman, T., Zhan, Z., Robey, R. W., Cristensen, B., Brangi, M., Greenberger, L., Dean, M. C., Fojo, T., et al. (1999) · Research at the University of Copenhagen (University of Copenhagen) · Cited by 929
Research works printed but not linked: 1
- Weishaupt, 1976, Idntification of singlet oxygen as the cytotoxic agent in photoinactivation of murine tumors, Cancer Res., 36, 2326
Cited by
Wang, W., Tabu, K., Hagiya, Y., Sugiyama, Y., Kokubu, Y., Murota, Y., Ogura, S., & Taga, T. (2017) · Scientific Reports · doi:10.1038/srep42070 · Cited by 70
Self-citationIntraoperative imaging techniques for glioma surgery
Garzón-Muvdi, T., Kut, C., Li, X. D., & Chaichana, K. L. (2017) · Future Oncology · doi:10.2217/fon-2017-0092 · Cited by 60
Matsuo, K., Yabuki, Y., & Fukunaga, K. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.107975 · Cited by 56
Ibarra, L. E., Vilchez, M. L., Caverzán, M. D., & Sanabria, L. N. M. (2020) · Journal of Neuroscience Research · doi:10.1002/jnr.24776 · Cited by 48
Fujishiro, T., Nonoguchi, N., Pavlyukov, M. S., Ohmura, N., Kawabata, S., Park, Y., Kajimoto, Y., Ishikawa, T., Nakano, I., & Kuroiwa, T. (2018) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2018.07.004 · Cited by 45
Self-citation
Metadata
- Authors
- Ishikawa, T., Takahashi, K., Ikeda, N., Kajimoto, Y., Hagiya, Y., Ogura, S.-I., Miyatake, S.-I., & Kuroiwa, T.
- Affiliations
- RIKEN (JP)
- Department of Neurosurgery, Osaka Medical College, Osaka 569-8686, Japan
- Tokyo Institute of Technology (JP)
- Corresponding author
- Ishikawa, Toshihisa
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2011-09-14
- Volume
- 3
- Issue
- 3
- Pages
- 615-635
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC3857086
- OpenAlex
- W2021649659
- Cited by
- 34
- References
- 76
- Citations by year
- 2026: 1 · 2024: 2 · 2023: 2 · 2022: 3 · 2021: 3 · 2020: 6 · 2019: 2 · 2018: 4 · 2017: 4 · 2016: 2 · 2015: 3 · 2014: 1 · 2013: 1
- FWCI
- 0.32
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Tokyo Tech Research Repository (Tokyo Institute of Technology) (submittedVersion)
- Funders
- Astellas Pharma
- Astellas Foundation for Research on Metabolic Disorders
- Japan Society for the Promotion of Science (20791022, 23650619, 19591709, 20591729, 23592147)
- Japan Science and Technology Agency
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Photodynamic Therapy Research Studies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- photodynamic diagnosis, 5-aminolevulinic acid, ABCG2, ABC transporter inhibitors, glioblastoma, protoporphyrin IX, ABC transporters, protein kinase inhibitors, fluorescence-guided surgery, QSAR, molecular design, brain tumors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Transporter-Mediated Drug Interaction Strategy for 5-Aminolevulinic Acid (ALA)-Based Photodynamic Diagnosis of Malignant Brain Tumor: Molecular Design of ABCG2 Inhibitors. https://app.cochat.ai/papers/10.3390/pharmaceutics3030615
- The paper
- Ishikawa, T., Takahashi, K., Ikeda, N., Kajimoto, Y., Hagiya, Y., Ogura, S.-I., Miyatake, S.-I., & Kuroiwa, T. (2011). Transporter-Mediated Drug Interaction Strategy for 5-Aminolevulinic Acid (ALA)-Based Photodynamic Diagnosis of Malignant Brain Tumor: Molecular Design of ABCG2 Inhibitors. Pharmaceutics. https://doi.org/10.3390/pharmaceutics3030615
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.